Literature DB >> 10067684

Mucosal immunogenicity and adjuvanticity of cholera toxin in swine.

D L Foss1, M P Murtaugh.   

Abstract

The oral immunogenic and adjuvant properties of cholera toxin (CT) and its nontoxic B subunit (CT-B) were assessed in swine. Both whole CT and CT-B are oral immunogens in swine and CT is relatively more potent. Oral administration of 100 microg of CT resulted in a greater immune response than 1 mg of CT-B as measured by anti-CT-B IgA, IgG and IgM in local (jejunum) and distant (oral cavity) mucosal sites, and in systemic sites including blood and spleen. Lower doses of CT were potent adjuvants for the response to CT-B, but did not induce detectable immunity alone. The predominant response to oral CT-B administered with CT was intestinally produced and secreted IgA, with about 2500 per 10(6) jejunal lamina propria cells producing anti-CT-B IgA in immunized animals. While CT is a potent adjuvant for CT-B, its ability to act as adjuvant for heterologous proteins is more restricted. 50 microg of CT in combination with 1 mg of CT-B did not induce antibodies to 25 mg of coadministered KLH. However, chemical linking of ovalbumin to CT-B and coadministration with CT resulted in a detectable antibody response to ovalbumin. These results suggest that CT is immunogenic and is a potent adjuvant for CT-B in swine and that the induction of mucosal immunity to heterologous antigens may require specific targeting to the gut-associated lymphoid tissues.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10067684     DOI: 10.1016/s0264-410x(98)00263-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Immune responses elicited in mice with recombinant Lactococcus lactis expressing F4 fimbrial adhesin FaeG by oral immunization.

Authors:  Shujie Liu; Yongming Li; Ziwei Xu; Yicheng Wang
Journal:  Vet Res Commun       Date:  2010-06-09       Impact factor: 2.459

2.  Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs.

Authors:  Valeria Alcon; Maria Baca-Estrada; Marco Vega-Lopez; Philip Willson; Lorne A Babiuk; Praveen Kumar; Rolf Hecker; Marianna Foldvari
Journal:  AAPS J       Date:  2005-10-14       Impact factor: 4.009

Review 3.  Advances in swine immunology help move vaccine technology forward.

Authors:  Michael P Murtaugh
Journal:  Vet Immunol Immunopathol       Date:  2014-02-23       Impact factor: 2.046

4.  Differential regulation of macrophage interleukin-1 (IL-1), IL-12, and CD80-CD86 by two bacterial toxins.

Authors:  D L Foss; M J Zilliox; M P Murtaugh
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

5.  Colostral antibody-mediated and cell-mediated immunity contributes to innate and antigen-specific immunity in piglets.

Authors:  Meggan Bandrick; Claudia Ariza-Nieto; Samuel K Baidoo; Thomas W Molitor
Journal:  Dev Comp Immunol       Date:  2013-11-16       Impact factor: 3.636

6.  Oral vaccine formulations stimulate mucosal and systemic antibody responses against staphylococcal enterotoxin B in a piglet model.

Authors:  Tiffany K Inskeep; Chad Stahl; Jack Odle; Judy Oakes; Laura Hudson; Kenneth L Bost; Kenneth J Piller
Journal:  Clin Vaccine Immunol       Date:  2010-06-16

7.  Oral antigen exposure in newborn piglets circumvents induction of oral tolerance in response to intraperitoneal vaccination in later life.

Authors:  J Alex Pasternak; Siew Hon Ng; Rachelle M Buchanan; Sonja Mertins; George K Mutwiri; Volker Gerdts; Heather L Wilson
Journal:  BMC Vet Res       Date:  2015-03-07       Impact factor: 2.741

8.  Humoral immune and adjuvant responses of mucosally-administered Tinospora cordifolia immunomodulatory protein in BALB/c mice.

Authors:  Ivan Aranha; Yeldur P Venkatesh
Journal:  J Ayurveda Integr Med       Date:  2018-11-17

Review 9.  Evidence for a common mucosal immune system in the pig.

Authors:  Heather L Wilson; Milan R Obradovic
Journal:  Mol Immunol       Date:  2014-09-18       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.